Iron Triangle Partners LP Has $22.49 Million Stock Holdings in Glaukos Co. (NYSE:GKOS)

Iron Triangle Partners LP lowered its stake in Glaukos Co. (NYSE:GKOS) by 31.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 150,000 shares of the medical instruments supplier’s stock after selling 67,674 shares during the quarter. Glaukos makes up approximately 2.5% of Iron Triangle Partners LP’s investment portfolio, making the stock its 18th largest position. Iron Triangle Partners LP’s holdings in Glaukos were worth $22,491,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. IFP Advisors Inc acquired a new position in shares of Glaukos during the 4th quarter worth about $43,000. Asset Planning Inc acquired a new position in Glaukos during the fourth quarter worth approximately $90,000. CoreCap Advisors LLC raised its stake in Glaukos by 36.4% in the fourth quarter. CoreCap Advisors LLC now owns 750 shares of the medical instruments supplier’s stock valued at $112,000 after buying an additional 200 shares during the period. Picton Mahoney Asset Management acquired a new stake in shares of Glaukos in the fourth quarter valued at approximately $125,000. Finally, SBI Securities Co. Ltd. bought a new position in shares of Glaukos during the 4th quarter worth approximately $153,000. Institutional investors own 99.04% of the company’s stock.

Analysts Set New Price Targets

GKOS has been the subject of several research reports. Needham & Company LLC cut their price target on Glaukos from $176.00 to $115.00 and set a “buy” rating for the company in a report on Thursday, May 1st. Mizuho cut their target price on shares of Glaukos from $200.00 to $175.00 and set an “outperform” rating for the company in a research note on Wednesday, April 16th. Wells Fargo & Company lowered shares of Glaukos from an “overweight” rating to an “equal weight” rating and decreased their price target for the company from $160.00 to $86.00 in a research note on Thursday, May 1st. Stifel Nicolaus cut their price objective on shares of Glaukos from $140.00 to $115.00 and set a “buy” rating for the company in a research report on Thursday, May 1st. Finally, Stephens decreased their target price on Glaukos from $140.00 to $115.00 and set an “overweight” rating on the stock in a research report on Friday, May 2nd. One analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $134.67.

Glaukos Price Performance

Glaukos stock opened at $89.94 on Friday. The firm has a market cap of $5.14 billion, a PE ratio of -31.34 and a beta of 0.83. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71. The stock’s fifty day moving average price is $94.87 and its two-hundred day moving average price is $127.33. Glaukos Co. has a one year low of $77.10 and a one year high of $163.71.

Glaukos (NYSE:GKOS) last posted its quarterly earnings results on Wednesday, April 30th. The medical instruments supplier reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.11. The business had revenue of $106.66 million during the quarter, compared to the consensus estimate of $102.78 million. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. Glaukos’s revenue for the quarter was up 24.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.70) earnings per share. As a group, research analysts expect that Glaukos Co. will post -1.08 EPS for the current fiscal year.

Insider Activity at Glaukos

In other Glaukos news, CFO Alex R. Thurman sold 1,520 shares of the firm’s stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total value of $162,396.80. Following the sale, the chief financial officer now owns 53,431 shares in the company, valued at $5,708,568.04. This trade represents a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Tomas Navratil sold 3,416 shares of the company’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $147.14, for a total transaction of $502,630.24. Following the transaction, the insider now owns 72,437 shares of the company’s stock, valued at $10,658,380.18. This trade represents a 4.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 6.40% of the stock is currently owned by insiders.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.